“avowed anticancer agent Kevetrin, as yet with no proven clinical activity, was mired in an ongoing, ceaseless phase 1 trial, with doses being escalated far beyond a clinically appropriate dose in quest for a vaunted “maximum tolerated dose.” [-'Dr' KSS]

Your statement is totally incorrect and is the most important reason why you are drawing the wrong conclusion about Cellceutix.

All patients in all cohorts have their blood drawn and sent for “PK” analysis. The clinical investigator’s and our teams see the results and the Safety Review Committee decides whether to increase dosing is made based on this and safety data. If the “PK” data indicates the higher dose is more effective, of course we will increase dosing. Our recent statements that we expect to conclude the trial soon means the rate of increased benefit to increased dosing is getting narrower. It has zero to do with lets give the patient more drug. "